Lumosa Therapeutics

Lumosa Therapeutics (Stock code: 6535.TW)  is the "new drug development harbor in Taiwan," where scientific innovation meets visionary expertise. Our core competence lies in accelerating early-stage new drug introduction, optimizing development strategies, and fostering global licensing opportunities. Notably, LT1001, our long-acting analgesic injection, has gained marketing approvals in Taiwan, Singapore, Thailand, Malaysia and Ukraine, while LT3001's phase 2 trials for acute ischemic stroke treatment progress. Embracing our position as an international pharmaceutical R&D leader, Lumosa forges strategic alliances to minimize risks, accelerate product marketing, and elevate the standards of new drug development.

Investment time	2011
Incubation Successes	Center Ventures helped launch Lumosa Therapeutics Co., Ltd. with the merge of SunTen Phytotech Co., Ltd., Cheng Pang Biopharma Company, and BroadCan Company. It introduced experienced operation teams to bring operational synergies, such as adjusting product development strategies and operational focus, as well as accelerating product development timeline. Center Ventures is actively integrating relevant resources to support corporate decision-making between Lumosa and TPG Biologics, enriching Lumosa’s product pipeline with both small and large molecule novel drugs while maximizing investment benefits.
Milestones	Lumosa Therapeutics was publicly listed on Taipei Exchange in 2016 (Stock Code: 6535). Naldebain® was approved by Taiwan Food and Drug Administration (TFDA) in 2017. Lumosa’s lead drug candidate for acute ischemic stroke, LT3001, has received the approval from the USFDA to begin Phase I clinical trials and is expected to be completed in the second half of 2018. Completed the merger with TPG Biologics, Inc. in 2018, which will transform Lumosa into one of the leading new drug development companies for both small and large molecule novel drug candidates in Asia.